Cerevance
@cerevance
Followers
245
Following
19
Media
117
Statuses
237
Creating a world-class neuroscience company to advance new medicines for serious diseases
Joined December 2018
At Cerevance, we’re aiming to provide a new treatment option for individuals with #PD that shifts beyond dopamine, offering an entirely differentiated mechanism of action that can better improve daily life experiences. Read about it in @FierceBiotech:
fiercebiotech.com
While the prevalence of Parkinson’s disease (PD) has doubled over the past 20 years, the treatment paradigm has remained largely unchanged. | How Cerevance’s innovative, non-dopaminergic approach is...
0
0
0
We’re excited to present new data from our Phase 2 adjunctive study of solengepras at the #PSG2025 Annual Meeting today. Discover how solengepras demonstrated significant reductions in OFF time in individuals with #Parkinsons disease: https://t.co/rv34Lxpahh
0
0
0
Advancing Parkinson’s care with a novel, non-dopaminergic approach. Next week at the PSG Annual Meeting in San Diego, we’re excited to showcase solgenepras and its potential to address unmet needs in Parkinson’s disease. Learn about our presentations: https://t.co/4ZiE4GPyNL
0
0
0
We’re excited to share our latest research in obesity and neurodegenerative disorders driven by #neuroinflammation at the upcoming TD Cowen Treatment Advancements in Obesity and Related Disorders Summit. Learn about our panel discussion: https://t.co/y4sxaR43sG
0
0
0
We had a great time connecting with the global movement disorders community at last week’s #MDSCongress, where we presented findings from our Phase 2 ASCEND trial of solengepras. Learn more about how we’re driving innovation in #PD research: https://t.co/KrYKmCdo9x
0
0
0
Curious how our proprietary NETSseq platform is advancing drug discovery for #neurodegenerative disorders? Hear from our CEO, Craig Thompson, as he discusses our unique research capabilities with @PharmExec:
pharmexec.com
Craig Thompson, CEO of Cerevance touches on the NETSseq platform and how it shapes Cerevance's approach to the drug discovery strategy.
0
0
0
Join us at the 2025 #MDSCongress in Honolulu, where we’ll present the promising findings from our Phase 2 ASCEND trial of solengepras in patients with early, untreated #PD. Learn more about our oral presentation: https://t.co/IY0iuAu41T We hope to see you there!
0
0
0
Our global Phase 3 ARISE trial represents an important step in our efforts to drive progress in #Parkinsons research and better serve the needs of individuals living with #PD. Learn more: https://t.co/4pYSaRWKqu
0
0
0
On #WorldBrainDay, we highlight our commitment to advancing the understanding of neurological disorders, including #Parkinsons disease. Our Phase 3 ARISE trial represents a pivotal step in this mission. Learn more: https://t.co/tpidNhznpF
0
0
0
Our CEO, Craig Thompson, looks forward to presenting our latest research in Alzheimer’s and other #neurodegenerative diseases driven by neuroinflammation at #AAIC25 later this month. Check out our posters: https://t.co/D2I0NAtPIJ
0
0
0
Living with #PD can be daunting, but every day, new strides in research bring us closer to advancing novel treatment options for this community. Learn about our Phase 3 ARISE trial of solengepras in #PD and see if you qualify for enrollment: https://t.co/oTluC0b9x7
0
0
2
Our CEO, Craig Thompson, was at #BIO2025 last week, where he engaged in valuable discussions with leaders in the biotech community that will continue to inspire our efforts to tackle #CNS disorders. Learn more about our ongoing research:
cerevance.com
A team of world leading scientists and drug developers are utilizing the company’s proprietary NETSseq platform and advanced machine learning techniques to identify previously undiscovered gene...
A look back at an incredible week at #BIO2025, filled with connection, collaboration and inspiration - because the World Can’t Wait.
0
0
1
Dr. Stuart Isaacson recently participated in a discussion with @VJNeurology, highlighting how our clinical research could potentially provide a differentiated approach to the treatment of #PD. Check it out: https://t.co/aPZnMbI3kJ
0
0
1
Interested in learning more about our novel, non-dopaminergic approach for treating Parkinson’s disease? Read about our investigational therapy, solengepras, and the steps we’re taking to bring this treatment option to the #PD community: https://t.co/weo3Hi4b0N
0
0
2
Our investigational CVN293 is a highly selective oral inhibitor targeting KCNK13, a novel intervention point for disorders driven by #neuroinflammation, like obesity. Learn about our plans to advance this potential treatment option for various conditions: https://t.co/RMWo6iOsiG
0
0
2
Solengepras, our investigational, non-dopaminergic therapy for #ParkinsonsDisease offers a novel approach to treating both motor and non-motor functions while mitigating the side effects commonly associated with the current standard of care. Learn more: https://t.co/utGgSXJ9s0
0
0
2
We had a great time presenting our latest #neuroinflammatory and #neurodegerative research at #AANAM last week. Thank you to everyone who joined our poster sessions to learn more about our investigational therapies, solengepras and CVN293. #ICYMI: https://t.co/E95lLumV3i
0
0
2
Join us at #AAN2025 to hear about our latest research advancements in the #neurodegenerative disease space. For more details on what we’ll be presenting: https://t.co/E95lLumV3i
0
0
0
We’re back from #ADPD2025, where lead investigator Dr. Aaron Ellenbogen presented our Phase 2 ASCEND monotherapy trial results of solengepras, our investigational treatment for individuals with early, untreated #ParkinsonsDisease. Learn more: https://t.co/Beml7c7F5a
3
0
6
This #ParkinsonsAwarenessMonth, join us in supporting ongoing research to address the unmet needs of individuals impacted by Parkinson’s. Discover more about our Phase 3 ARISE trial of solengepras, our non-dopaminergic treatment option: https://t.co/utGgSXJ9s0
0
0
0